Further understanding of the molecular events altered by unregulated BCR-ABL1 signaling will aid in the design of novel therapeutics aimed at targeting refractory and blast crisis CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.